期刊
CURRENT OPINION IN VIROLOGY
卷 2, 期 5, 页码 588-598出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2012.08.002
关键词
-
类别
资金
- Fonds de la recherche en sante du Quebec (FRSQ)
- Canadian Institutes of Health Research (CIHR)
- Canadian Institutes for Health Research
- Novartis/Canadian Liver Foundation Hepatology Research Chair
The inclusion of NS3 protease inhibitors to the interferon-containing standard of care improved sustained viral response rates in hepatitis C virus (HCV) infected patients. However, there is still an unmet medical need as this drug regimen is poorly tolerated and lacks efficacy, especially in difficult-to-treat patients. Intense drug discovery and development efforts have focused on direct-acting antivirals (DAA) that target NS3 protease, NS5B polymerase and the NS5A protein. DAA combinations are currently assessed in clinical trials. Alternative antivirals have emerged that target host machineries co-opted by HCV. Finally, continuous and better understanding of HCV biology allows speculating on the value of novel classes of DAA required in future personalized all-oral interferon-free combination therapy and for supporting global disease eradication.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据